These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
327 related articles for article (PubMed ID: 26451105)
1. Sequential delivery of an anticancer drug and combined immunomodulatory nanoparticles for efficient chemoimmunotherapy. Heo MB; Kim SY; Yun WS; Lim YT Int J Nanomedicine; 2015; 10():5981-92. PubMed ID: 26451105 [TBL] [Abstract][Full Text] [Related]
2. Polymer nanoparticles for enhanced immune response: combined delivery of tumor antigen and small interference RNA for immunosuppressive gene to dendritic cells. Heo MB; Cho MY; Lim YT Acta Biomater; 2014 May; 10(5):2169-76. PubMed ID: 24394635 [TBL] [Abstract][Full Text] [Related]
3. Enhanced stimulation of anti-breast cancer T cells responses by dendritic cells loaded with poly lactic-co-glycolic acid (PLGA) nanoparticle encapsulated tumor antigens. Iranpour S; Nejati V; Delirezh N; Biparva P; Shirian S J Exp Clin Cancer Res; 2016 Oct; 35(1):168. PubMed ID: 27782834 [TBL] [Abstract][Full Text] [Related]
5. The effect of combined IL10 siRNA and CpG ODN as pathogen-mimicking microparticles on Th1/Th2 cytokine balance in dendritic cells and protective immunity against B cell lymphoma. Pradhan P; Qin H; Leleux JA; Gwak D; Sakamaki I; Kwak LW; Roy K Biomaterials; 2014 Jul; 35(21):5491-504. PubMed ID: 24720881 [TBL] [Abstract][Full Text] [Related]
6. Poly Lactic-co-Glycolic Acid Nanoparticles Containing Human Gastric Tumor Lysates as Antigen Delivery Vehicles for Dendritic Cell-Based Antitumor Immunotherapy. Kohnepoushi C; Nejati V; Delirezh N; Biparva P Immunol Invest; 2019 Nov; 48(8):794-808. PubMed ID: 31094258 [TBL] [Abstract][Full Text] [Related]
7. Induction of a balanced Th1/Th2 immune responses by co-delivery of PLGA/ovalbumin nanospheres and CpG ODNs/PEI-SWCNT nanoparticles as TLR9 agonist in BALB/c mice. Ebrahimian M; Hashemi M; Maleki M; Abnous K; Hashemitabar G; Ramezani M; Haghparast A Int J Pharm; 2016 Dec; 515(1-2):708-720. PubMed ID: 27989827 [TBL] [Abstract][Full Text] [Related]
8. Surface modification of poly(D,L-lactic-co-glycolic acid) nanoparticles with protamine enhanced cross-presentation of encapsulated ovalbumin by bone marrow-derived dendritic cells. Han R; Zhu J; Yang X; Xu H J Biomed Mater Res A; 2011 Jan; 96(1):142-9. PubMed ID: 21105162 [TBL] [Abstract][Full Text] [Related]
9. Programmed nanoparticles for combined immunomodulation, antigen presentation and tracking of immunotherapeutic cells. Heo MB; Lim YT Biomaterials; 2014 Jan; 35(1):590-600. PubMed ID: 24125775 [TBL] [Abstract][Full Text] [Related]
10. Development of a poly(d,l-lactic-co-glycolic acid) nanoparticle formulation of STAT3 inhibitor JSI-124: implication for cancer immunotherapy. Molavi O; Mahmud A; Hamdy S; Hung RW; Lai R; Samuel J; Lavasanifar A Mol Pharm; 2010 Apr; 7(2):364-74. PubMed ID: 20030320 [TBL] [Abstract][Full Text] [Related]
11. Toll-like receptor 3-induced immune response by poly(d,l-lactide-co-glycolide) nanoparticles for dendritic cell-based cancer immunotherapy. Han HD; Byeon Y; Kang TH; Jung ID; Lee JW; Shin BC; Lee YJ; Sood AK; Park YM Int J Nanomedicine; 2016; 11():5729-5742. PubMed ID: 27843314 [TBL] [Abstract][Full Text] [Related]
12. Stimuli-responsive magnetic silica-poly-lactic-co-glycolic acid hybrid nanoparticles for targeted cancer chemo-immunotherapy. Gupta A; Niveria K; Chandpa HH; Singh M; Kumar V; Panda AK; Meena J Drug Deliv Transl Res; 2024 Oct; 14(10):2712-2726. PubMed ID: 38347431 [TBL] [Abstract][Full Text] [Related]
13. Vitamin E-Oligo(methyl diglycol l-glutamate) as a Biocompatible and Functional Surfactant for Facile Preparation of Active Tumor-Targeting PLGA Nanoparticles. Wu J; Zhang J; Deng C; Meng F; Zhong Z Biomacromolecules; 2016 Jul; 17(7):2367-74. PubMed ID: 27305935 [TBL] [Abstract][Full Text] [Related]
14. Polymer nanoparticles for cross-presentation of exogenous antigens and enhanced cytotoxic T-lymphocyte immune response. Song C; Noh YW; Lim YT Int J Nanomedicine; 2016; 11():3753-64. PubMed ID: 27540289 [TBL] [Abstract][Full Text] [Related]
15. "Pathogen-mimicking" nanoparticles for vaccine delivery to dendritic cells. Elamanchili P; Lutsiak CM; Hamdy S; Diwan M; Samuel J J Immunother; 2007; 30(4):378-95. PubMed ID: 17457213 [TBL] [Abstract][Full Text] [Related]
16. Rationalizing the use of functionalized poly-lactic-co-glycolic acid nanoparticles for dendritic cell-based targeted anticancer therapy. Kokate RA; Chaudhary P; Sun X; Thamake SI; Maji S; Chib R; Vishwanatha JK; Jones HP Nanomedicine (Lond); 2016; 11(5):479-94. PubMed ID: 26892440 [TBL] [Abstract][Full Text] [Related]
17. X-shaped DNA potentiates therapeutic efficacy in colitis-associated colon cancer through dual activation of TLR9 and inflammasomes. Koo JE; Shin SW; Um SH; Lee JY Mol Cancer; 2015 May; 14():104. PubMed ID: 25971982 [TBL] [Abstract][Full Text] [Related]
18. The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment. Yang M; Li J; Gu P; Fan X Bioact Mater; 2021 Jul; 6(7):1973-1987. PubMed ID: 33426371 [TBL] [Abstract][Full Text] [Related]
19. Biodegradable microparticles loaded with doxorubicin and CpG ODN for in situ immunization against cancer. Makkouk A; Joshi VB; Wongrakpanich A; Lemke CD; Gross BP; Salem AK; Weiner GJ AAPS J; 2015 Jan; 17(1):184-93. PubMed ID: 25331103 [TBL] [Abstract][Full Text] [Related]
20. Erythrocyte Membrane-Enveloped Polymeric Nanoparticles as Nanovaccine for Induction of Antitumor Immunity against Melanoma. Guo Y; Wang D; Song Q; Wu T; Zhuang X; Bao Y; Kong M; Qi Y; Tan S; Zhang Z ACS Nano; 2015 Jul; 9(7):6918-33. PubMed ID: 26153897 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]